Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Salaahuddin Dakhlalla

Psychiatry Whitfield, MS Medical Doctor

NPI 1881127876 CMS profile 3805441

3550 Highway 468 W, Whitfield, MS 39193

Open in the dashboard

General payments

$3,755

175 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Salaahuddin Dakhlalla of Whitfield, MS is reported in the CMS Open Payments database as having received $3,755 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $688 31
2024 General $680 29
2023 General $863 38
2022 General $961 48
2021 General $564 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Salaahuddin Dakhlalla
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Salaahuddin Dakhlalla were reported at $688. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Salaahuddin Dakhlalla Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $564 $143 $43–$576 $132
2022 $961 $153 $50–$590 $149
2023 $863 $170 $56–$651 $160
2024 $680 $179 $57–$673 $164
2025 $688 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $789 36 payments
  2. Neurocrine Biosciences, Inc. $529 25 payments
  3. Teva Pharmaceuticals USA, Inc. $492 24 payments
  4. Lundbeck LLC $467 20 payments
  5. Janssen Pharmaceuticals, Inc $434 20 payments
  6. Otsuka America Pharmaceutical, Inc. $296 15 payments
  7. AbbVie, Inc. $197 8 payments
  8. Vanda Pharmaceuticals Inc. $161 9 payments
  9. Avanir Pharmaceuticals, Inc. $127 6 payments
  10. E.R. Squibb & Sons, L.L.C. $115 6 payments
  11. Other $148 6 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,755 175 payments
Products named General payments · program years 2021–2025
  1. ARISTADA Cns $753 34 payments
  2. ARISTADA Cns $753 34 payments
  3. LYBALVI Cns $644 28 payments
  4. ABILIFY MAINTENA $551 26 payments
  5. INVEGA SUSTENNA $483 21 payments
  6. INGREZZA $447 20 payments
  7. ARISTADA INITIO $438 22 payments
  8. ARISTADA Cns $430 18 payments
  9. ARISTADA Cns $430 18 payments
  10. LYBALVI Cns $329 16 payments
  11. Other $1,980 96 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record